When it comes to using topical solutions to treat burns, a new drug may not be the best option
On Tuesday, the U.S. Food and Drug Administration announced that it will begin approving the first drug to treat acute skin infections with ofloxacetin ocular solutions.
The new drug, L-6-p-sulfate, will be given to people with severe, chronic, or refractory infections, which are caused by bacteria such as Staphylococcus aureus or E.coli.
Ofloxacein ogloAcetate, the active ingredient in the oflOXacin solution, is also being evaluated as a potential antibiotic in people with chronic infections.
The FDA said in a statement that the drug will not be approved for treating people who have never had a skin infection.
The approval of the drug, however, comes with a cautionary note.
“This drug is not a drug for treating burn or skin conditions that are already treatable by other medical therapies, and should not be considered for use in patients with severe or chronic skin conditions who require immediate hospitalization,” the agency said in its announcement.
In the U, people with a skin condition like acne, psoriasis, or psoropharyngitis often need to be treated in hospital.
In a statement, the FDA said it expects the drug to be available for sale in the U by mid-2018.
The drug will be approved under the U and FDA-approved drugs category.
Of the eight drugs approved by the FDA, five are currently available in the United States: ofloxicam (Olfactin), ofloxin (Klotho), ofliogastrol (Vasalgel), and ofloxyacetic acid (Caspaxin).